ClinicalTrials.gg
CompletedNCT05630287Updated Apr 23, 2025Results posted

A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants

A Phase 1 interventional study of [14C]-Selpercatinib and Selpercatinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-23.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 4 years 3 months after the study started (first participant enrolled Aug 2018, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it and also to assess the pharmacokinetics (PK), metabolism, and routes and extent of elimination of selpercatinib in healthy male participants. The study will last up to 59 days (Part 1) or 46 days (Part 2) including screening and 7-day safety follow-up.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meter squared (kg/m²)
  • Have normal blood pressure, pulse rate, (ECG), and blood and urine laboratory test results that are acceptable for the study
  • Participants will be surgically sterile for at least 90 days prior to Check in or, when sexually active with female partners of , will agree to use effective methods or abstain from sexual intercourse from the time of first dose through 90 days after study drug administration

Exclusion criteria

Exclusion Criteria:

  • Participation in any other radiolabeled study drug trial within 12 months prior to Check-in
  • Exposure to significant radiation (eg, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to Check-in
  • Use or intention to use any medications/products known strong inducers or inhibitors of Cytochrome P450 3A4 enzymes, including St. John's wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Carbon-14-labelled [14C]-Selpercatinib - Part 1

    Participants received a single oral dose of 165 milligram (mg) of \[14C\]-Selpercatinib (containing approximately 40 µCi).

    Drug: [14C]-Selpercatinib

  • Experimental
    Selpercatinib and [14C]-Selpercatinib - Part 2

    Participants received a single oral dose of 160 mg Selpercatinib followed by single dose of \<100 µg of \[14C\]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV).

    Drug: Selpercatinib · Drug: [14C]-Selpercatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Selpercatinib in Plasma (Part 1)

    PK: AUClast of Selpercatinib in plasma

    Time frame: PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  2. PK: AUClast of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

    PK: AUClast of \[14C\] Selpercatinib in plasma and whole blood

    Time frame: PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  3. PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma (Part 1)

    PK: AUC0-inf of Selpercatinib in plasma

    Time frame: PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  4. PK: AUC0-inf of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

    PK: AUC0-inf of \[14C\] Selpercatinib in plasma and whole blood

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  5. PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib in Plasma (Part 1)

    PK: AUC0-24 of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose

  6. PK: (AUC0-24) of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

    PK: AUC0-24 of \[14C\] Selpercatinib in plasma and whole blood

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose

  7. PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma (Part 1)

    PK: Cmax of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  8. PK: Cmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

    PK: Cmax of \[14C\] Selpercatinib in plasma and whole blood

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  9. PK: Time to Reach Cmax (Tmax) of Selpercatinib in Plasma (Part 1)

    PK: Tmax of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  10. PK: Tmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

    PK: Tmax of \[14C\] Selpercatinib in plasma and whole blood

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  11. PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma (Part 1)

    PK: t½ of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  12. PK: t½ of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

    PK: t½ of \[14C\] Selpercatinib in plasma and whole blood

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  13. PK: Apparent Systemic Clearance (CL/F) of Selpercatinibin Plasma (Part 1)

    PK: CL/F of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  14. PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Selpercatinib in Plasma (Part 1)

    PK: Vz/F of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  15. PK: Plasma Selpercatinib/Total Radioactivity AUC0-24 Ratio (Part 1)

    PK: AUC0-24 of Selpercatinib in plasma/AUC0-24 of total radioactivity in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose

  16. PK: Blood/Plasma Total Radioactivity AUC0-24 Ratio (Part 1)

    PK: AUC0-24 of total radioactivity in whole blood/AUC0-24 of total radioactivity in whole blood

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose

  17. PK: AUClast of Selpercatinib in Plasma (Part 2)

    PK: AUClast of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  18. PK: AUClast of [14C] Selpercatinib in Plasma (Part 2)

    PK: AUClast of \[14C\] Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  19. PK: AUC0-inf of Selpercatinib in Plasma (Part 2)

    PK: AUC0-inf of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  20. PK: AUC0-inf of [14C] Selpercatinib in Plasma (Part 2)

    PK: AUC0-inf of \[14C\] Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  21. PK: Cmax of Selpercatinib in Plasma (Part 2)

    PK: Cmax of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  22. PK: Cmax of [14C] Selpercatinib in Plasma (Part 2)

    PK: Cmax of \[14C\] Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  23. PK: Tmax of Selpercatinib in Plasma (Part 2)

    PK: Tmax of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  24. PK: Tmax of [14C] Selpercatinib in Plasma (Part 2)

    PK: Tmax of \[14C\] Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  25. PK: t½ of Selpercatinib in Plasma (Part 2)

    PK: t½ of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  26. PK: t½ of [14C] Selpercatinib in Plasma (Part 2)

    PK: t½ of \[14C\] Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  27. PK: CL/F of Selpercatinib in Plasma (Part 2)

    PK: CL/F of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  28. PK: Systemic Clearance (CL) of [14C] Selpercatinib in Plasma (Part 2)

    PK: CL of \[14C\] Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  29. PK: Vz/F of Selpercatinib in Plasma (Part 2)

    PK: Vz/F of Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  30. PK: Volume of Distribution During the Terminal Phase (Vz) of [14C] Selpercatinib in Plasma (Part 2)

    PK: Vz of \[14C\] Selpercatinib in plasma

    Time frame: Pre-dose up to 168 hour post-dose

  31. PK: Volume of Distribution at Steady State (Vss) of [14C] Selpercatinib in Plasma (Part 2)

    PK: Vss of \[14C\] Selpercatinib in plasma

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

  32. PK: Absolute Bioavailability (F) of Selpercatinib in Plasma (Part 2)

    Absolute bioavailability was determined by comparing the plasma exposure of LOXO-292 following oral dosing with the plasma exposure of \[14C\]-LOXO-292 following IV dosing.

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose

07

Results

Posted Apr 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneCarbon-14-labelled [14C]-Selpercatinib - Part 1Selpercatinib and [14C]-Selpercatinib - Part 2
Started66
Received at least 1 dose of study drug66
Completed66
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Selpercatinib in Plasma (Part 1)

PK: AUClast of Selpercatinib in plasma

Time frame:
PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Selpercatinib in Plasma (Part 1)
hour*nanogram per milliliter (h*ng/mL)[14C]-Selpercatinib - Part 1
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Selpercatinib in Plasma (Part 1)24100 ± 20.2
PrimaryPK: AUClast of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

PK: AUClast of \[14C\] Selpercatinib in plasma and whole blood

Time frame:
PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · h*ng equivalents per gram (h*ng Eq/g)
PK: AUClast of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
h*ng equivalents per gram (h*ng Eq/g)[14C]-Selpercatinib - Part 1
Plasma21400 ± 21.9
Whole Blood11400 ± 38.2
PrimaryPK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma (Part 1)

PK: AUC0-inf of Selpercatinib in plasma

Time frame:
PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · hours*nanogram per milliliter (h*ng/mL)
PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma (Part 1)
hours*nanogram per milliliter (h*ng/mL)[14C]-Selpercatinib - Part 1
PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma (Part 1)24200 ± 20.2
PrimaryPK: AUC0-inf of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

PK: AUC0-inf of \[14C\] Selpercatinib in plasma and whole blood

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · h*ng Eq/g
PK: AUC0-inf of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
h*ng Eq/g[14C]-Selpercatinib - Part 1
Plasma26900 ± 25.8
Whole Blood16700 ± 32.8
PrimaryPK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib in Plasma (Part 1)

PK: AUC0-24 of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib in Plasma (Part 1)
h*ng/mL[14C]-Selpercatinib - Part 1
PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib in Plasma (Part 1)17100 ± 17.7
PrimaryPK: (AUC0-24) of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

PK: AUC0-24 of \[14C\] Selpercatinib in plasma and whole blood

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
Reported as:
Geometric mean · h*ng Eq/g
PK: (AUC0-24) of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
h*ng Eq/g[14C]-Selpercatinib - Part 1
Plasma21400 ± 21.9
Whole Blood12600 ± 23.4
PrimaryPK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma (Part 1)

PK: Cmax of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma (Part 1)
ng/mL[14C]-Selpercatinib - Part 1
PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma (Part 1)1890 ± 22.7
PrimaryPK: Cmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

PK: Cmax of \[14C\] Selpercatinib in plasma and whole blood

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · nanogram equivalents per gram (ng Eq/g)
PK: Cmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
nanogram equivalents per gram (ng Eq/g)[14C]-Selpercatinib - Part 1
Plasma2240 ± 24.6
Whole Blood1260 ± 25.8
PrimaryPK: Time to Reach Cmax (Tmax) of Selpercatinib in Plasma (Part 1)

PK: Tmax of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Median · hour (h)
PK: Time to Reach Cmax (Tmax) of Selpercatinib in Plasma (Part 1)
hour (h)[14C]-Selpercatinib - Part 1
PK: Time to Reach Cmax (Tmax) of Selpercatinib in Plasma (Part 1)1.25 (1.00 to 1.50)
PrimaryPK: Tmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

PK: Tmax of \[14C\] Selpercatinib in plasma and whole blood

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Median · h
PK: Tmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
h[14C]-Selpercatinib - Part 1
Plasma1.50 (1.00 to 1.50)
Whole Blood1.50 (1.00 to 2.00)
PrimaryPK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma (Part 1)

PK: t½ of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · h
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma (Part 1)
h[14C]-Selpercatinib - Part 1
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma (Part 1)36.5 ± 18.0
PrimaryPK: t½ of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity

PK: t½ of \[14C\] Selpercatinib in plasma and whole blood

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · h
PK: t½ of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
h[14C]-Selpercatinib - Part 1
Plasma12.2 ± 2.36
Whole Blood10.5 ± 2.79
PrimaryPK: Apparent Systemic Clearance (CL/F) of Selpercatinibin Plasma (Part 1)

PK: CL/F of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · Liter per hour (L/h)
PK: Apparent Systemic Clearance (CL/F) of Selpercatinibin Plasma (Part 1)
Liter per hour (L/h)[14C]-Selpercatinib - Part 1
PK: Apparent Systemic Clearance (CL/F) of Selpercatinibin Plasma (Part 1)6.83 ± 20.2
PrimaryPK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Selpercatinib in Plasma (Part 1)

PK: Vz/F of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · Liter (L)
PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Selpercatinib in Plasma (Part 1)
Liter (L)[14C]-Selpercatinib - Part 1
PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Selpercatinib in Plasma (Part 1)323 ± 45.0
PrimaryPK: Plasma Selpercatinib/Total Radioactivity AUC0-24 Ratio (Part 1)

PK: AUC0-24 of Selpercatinib in plasma/AUC0-24 of total radioactivity in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose
Reported as:
Geometric mean · Ratio
PK: Plasma Selpercatinib/Total Radioactivity AUC0-24 Ratio (Part 1)
Ratio[14C]-Selpercatinib - Part 1
PK: Plasma Selpercatinib/Total Radioactivity AUC0-24 Ratio (Part 1)0.799 ± 4.4
PrimaryPK: Blood/Plasma Total Radioactivity AUC0-24 Ratio (Part 1)

PK: AUC0-24 of total radioactivity in whole blood/AUC0-24 of total radioactivity in whole blood

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
Reported as:
Geometric mean · Ratio
PK: Blood/Plasma Total Radioactivity AUC0-24 Ratio (Part 1)
Ratio[14C]-Selpercatinib - Part 1
PK: Blood/Plasma Total Radioactivity AUC0-24 Ratio (Part 1)0.590 ± 9.0
PrimaryPK: AUClast of Selpercatinib in Plasma (Part 2)

PK: AUClast of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · hour*picogram per mL (h*pg/mL)
PK: AUClast of Selpercatinib in Plasma (Part 2)
hour*picogram per mL (h*pg/mL)Selpercatinib and [14C]-Selpercatinib - Part 2
PK: AUClast of Selpercatinib in Plasma (Part 2)20200 ± 26.6
PrimaryPK: AUClast of [14C] Selpercatinib in Plasma (Part 2)

PK: AUClast of \[14C\] Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · h*pg/mL
PK: AUClast of [14C] Selpercatinib in Plasma (Part 2)
h*pg/mLSelpercatinib and [14C]-Selpercatinib - Part 2
PK: AUClast of [14C] Selpercatinib in Plasma (Part 2)1680 ± 30.0
PrimaryPK: AUC0-inf of Selpercatinib in Plasma (Part 2)

PK: AUC0-inf of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · h*pg/mL
PK: AUC0-inf of Selpercatinib in Plasma (Part 2)
h*pg/mLSelpercatinib and [14C]-Selpercatinib - Part 2
PK: AUC0-inf of Selpercatinib in Plasma (Part 2)20300 ± 26.6
PrimaryPK: AUC0-inf of [14C] Selpercatinib in Plasma (Part 2)

PK: AUC0-inf of \[14C\] Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · h*pg/mL
PK: AUC0-inf of [14C] Selpercatinib in Plasma (Part 2)
h*pg/mLSelpercatinib and [14C]-Selpercatinib - Part 2
PK: AUC0-inf of [14C] Selpercatinib in Plasma (Part 2)1720 ± 33.5
PrimaryPK: Cmax of Selpercatinib in Plasma (Part 2)

PK: Cmax of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Selpercatinib in Plasma (Part 2)
ng/mLSelpercatinib and [14C]-Selpercatinib - Part 2
PK: Cmax of Selpercatinib in Plasma (Part 2)1550 ± 28.0
PrimaryPK: Cmax of [14C] Selpercatinib in Plasma (Part 2)

PK: Cmax of \[14C\] Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of [14C] Selpercatinib in Plasma (Part 2)
ng/mLSelpercatinib and [14C]-Selpercatinib - Part 2
PK: Cmax of [14C] Selpercatinib in Plasma (Part 2)201 ± 30.0
PrimaryPK: Tmax of Selpercatinib in Plasma (Part 2)

PK: Tmax of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Median · h
PK: Tmax of Selpercatinib in Plasma (Part 2)
hSelpercatinib and [14C]-Selpercatinib - Part 2
PK: Tmax of Selpercatinib in Plasma (Part 2)1.92 (1.00 to 1.92)
PrimaryPK: Tmax of [14C] Selpercatinib in Plasma (Part 2)

PK: Tmax of \[14C\] Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Median · h
PK: Tmax of [14C] Selpercatinib in Plasma (Part 2)
hSelpercatinib and [14C]-Selpercatinib - Part 2
PK: Tmax of [14C] Selpercatinib in Plasma (Part 2)0.167 (0.167 to 2.10)
PrimaryPK: t½ of Selpercatinib in Plasma (Part 2)

PK: t½ of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · h
PK: t½ of Selpercatinib in Plasma (Part 2)
hSelpercatinib and [14C]-Selpercatinib - Part 2
PK: t½ of Selpercatinib in Plasma (Part 2)31.5 ± 20.7
PrimaryPK: t½ of [14C] Selpercatinib in Plasma (Part 2)

PK: t½ of \[14C\] Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Mean · h
PK: t½ of [14C] Selpercatinib in Plasma (Part 2)
hSelpercatinib and [14C]-Selpercatinib - Part 2
PK: t½ of [14C] Selpercatinib in Plasma (Part 2)16.9 ± 7.97
PrimaryPK: CL/F of Selpercatinib in Plasma (Part 2)

PK: CL/F of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · L/h
PK: CL/F of Selpercatinib in Plasma (Part 2)
L/hSelpercatinib and [14C]-Selpercatinib - Part 2
PK: CL/F of Selpercatinib in Plasma (Part 2)7.89 ± 26.6
PrimaryPK: Systemic Clearance (CL) of [14C] Selpercatinib in Plasma (Part 2)

PK: CL of \[14C\] Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · L/h
PK: Systemic Clearance (CL) of [14C] Selpercatinib in Plasma (Part 2)
L/hSelpercatinib and [14C]-Selpercatinib - Part 2
PK: Systemic Clearance (CL) of [14C] Selpercatinib in Plasma (Part 2)5.70 ± 33.4
PrimaryPK: Vz/F of Selpercatinib in Plasma (Part 2)

PK: Vz/F of Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · L
PK: Vz/F of Selpercatinib in Plasma (Part 2)
LSelpercatinib and [14C]-Selpercatinib - Part 2
PK: Vz/F of Selpercatinib in Plasma (Part 2)307 ± 66.3
PrimaryPK: Volume of Distribution During the Terminal Phase (Vz) of [14C] Selpercatinib in Plasma (Part 2)

PK: Vz of \[14C\] Selpercatinib in plasma

Time frame:
Pre-dose up to 168 hour post-dose
Reported as:
Geometric mean · L
PK: Volume of Distribution During the Terminal Phase (Vz) of [14C] Selpercatinib in Plasma (Part 2)
LSelpercatinib and [14C]-Selpercatinib - Part 2
PK: Volume of Distribution During the Terminal Phase (Vz) of [14C] Selpercatinib in Plasma (Part 2)127 ± 56.8
PrimaryPK: Volume of Distribution at Steady State (Vss) of [14C] Selpercatinib in Plasma (Part 2)

PK: Vss of \[14C\] Selpercatinib in plasma

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · L
PK: Volume of Distribution at Steady State (Vss) of [14C] Selpercatinib in Plasma (Part 2)
LSelpercatinib and [14C]-Selpercatinib - Part 2
PK: Volume of Distribution at Steady State (Vss) of [14C] Selpercatinib in Plasma (Part 2)85.0 ± 21.0
PrimaryPK: Absolute Bioavailability (F) of Selpercatinib in Plasma (Part 2)

Absolute bioavailability was determined by comparing the plasma exposure of LOXO-292 following oral dosing with the plasma exposure of \[14C\]-LOXO-292 following IV dosing.

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · Ratio
PK: Absolute Bioavailability (F) of Selpercatinib in Plasma (Part 2)
RatioSelpercatinib and [14C]-Selpercatinib - Part 2
PK: Absolute Bioavailability (F) of Selpercatinib in Plasma (Part 2)0.732 ± 13.9

Adverse events

Collected over Part 1: Baseline up to Day 29; Part 2: Baseline up to Day 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carbon-14-labelled [14C]-Selpercatinib0/6 (0%)0/6 (0%)4/6 (66.7%)
Selpercatinib and [14C]-Selpercatinib0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventCarbon-14-labelled [14C]-SelpercatinibSelpercatinib and [14C]-Selpercatinib
DiarrhoeaGastrointestinal disorders3/60/6
NauseaGastrointestinal disorders2/60/6
Abdominal painGastrointestinal disorders1/60/6
Dry mouthGastrointestinal disorders0/61/6
VomitingGastrointestinal disorders1/60/6
HeadacheNervous system disorders1/60/6
Hot flushVascular disorders1/60/6

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Carbon-14-labelled [14C]-Selpercatinib - Part 1Selpercatinib and [14C]-Selpercatinib - Part 2Total
Mean35 ± 12.532 ± 6.234 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Carbon-14-labelled [14C]-Selpercatinib - Part 1Selpercatinib and [14C]-Selpercatinib - Part 2Total
Female000
Male6612
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Carbon-14-labelled [14C]-Selpercatinib - Part 1Selpercatinib and [14C]-Selpercatinib - Part 2Total
Hispanic or Latino112
Not Hispanic or Latino5510
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Carbon-14-labelled [14C]-Selpercatinib - Part 1Selpercatinib and [14C]-Selpercatinib - Part 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American224
White448
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Carbon-14-labelled [14C]-Selpercatinib - Part 1Selpercatinib and [14C]-Selpercatinib - Part 2Total
United States6612
08

Study locations

1 site
  • LabCorp CRU, Inc.
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Sep 2018, 1 month.

Results were first posted in Apr 2025, 6 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Nov 29, 2022
StartActual
Aug 1, 2018
Primary completionActual
Sep 24, 2018
CompletionActual
Sep 24, 2018
Results first posted
Apr 23, 2025
Last update
Apr 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05630287
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Nov 29, 2022
Start date
Aug 1, 2018
Primary completion
Sep 24, 2018
Completion
Sep 24, 2018
Results posted
Apr 23, 2025
Last update
Apr 23, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion